HK1066170A1 - 6-substitued pyrido-pyrimidines - Google Patents

6-substitued pyrido-pyrimidines

Info

Publication number
HK1066170A1
HK1066170A1 HK04109141A HK04109141A HK1066170A1 HK 1066170 A1 HK1066170 A1 HK 1066170A1 HK 04109141 A HK04109141 A HK 04109141A HK 04109141 A HK04109141 A HK 04109141A HK 1066170 A1 HK1066170 A1 HK 1066170A1
Authority
HK
Hong Kong
Prior art keywords
substitued
pyrido
pyrimidines
substitued pyrido
Prior art date
Application number
HK04109141A
Other languages
English (en)
Inventor
Jian Jeffrey Chen
James Patrick Dunn
David Michael Goldstein
Christoph Martin Stahl
Original Assignee
Hoffman La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffman La Roche Ag filed Critical Hoffman La Roche Ag
Publication of HK1066170A1 publication Critical patent/HK1066170A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK04109141A 2001-02-12 2004-11-19 6-substitued pyrido-pyrimidines HK1066170A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26837501P 2001-02-12 2001-02-12
US33465401P 2001-11-30 2001-11-30
PCT/EP2002/001106 WO2002064594A2 (fr) 2001-02-12 2002-02-04 Pyrido-pyrimidines substituees en position 6

Publications (1)

Publication Number Publication Date
HK1066170A1 true HK1066170A1 (en) 2005-03-18

Family

ID=26953040

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04109141A HK1066170A1 (en) 2001-02-12 2004-11-19 6-substitued pyrido-pyrimidines

Country Status (32)

Country Link
US (3) US6696566B2 (fr)
EP (1) EP1361880B1 (fr)
JP (1) JP4064818B2 (fr)
KR (1) KR100639772B1 (fr)
CN (1) CN100376571C (fr)
AR (1) AR035854A1 (fr)
AT (1) ATE305303T1 (fr)
AU (1) AU2002256615B2 (fr)
BR (1) BRPI0207172B8 (fr)
CA (1) CA2434834C (fr)
CZ (1) CZ20032416A3 (fr)
DE (1) DE60206363T2 (fr)
DK (1) DK1361880T3 (fr)
ES (1) ES2249574T3 (fr)
HK (1) HK1066170A1 (fr)
HR (1) HRP20030624B1 (fr)
HU (1) HU229604B1 (fr)
IL (2) IL156872A0 (fr)
JO (1) JO2410B1 (fr)
MA (1) MA26993A1 (fr)
MX (1) MXPA03007166A (fr)
MY (1) MY131518A (fr)
NO (1) NO326133B1 (fr)
NZ (1) NZ526961A (fr)
PA (1) PA8539201A1 (fr)
PE (1) PE20020976A1 (fr)
PL (1) PL366918A1 (fr)
RU (1) RU2269527C2 (fr)
SK (1) SK11322003A3 (fr)
WO (1) WO2002064594A2 (fr)
YU (1) YU63703A (fr)
ZA (1) ZA200305938B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
CA2434834C (fr) 2001-02-12 2010-09-14 F. Hoffmann-La Roche Ag Pyrido-pyrimidines substituees en position 6
DK1470124T3 (da) * 2002-01-22 2006-04-18 Warner Lambert Co 2-(Pyridin-2-yl amino)-pyrido[2,3]pyrimidin-7-oner
AU2003215675B2 (en) 2002-04-03 2007-07-12 F. Hoffmann-La Roche Ag Imidazo fused compounds
RU2324695C2 (ru) * 2002-08-06 2008-05-20 Ф.Хоффманн-Ля Рош Аг 6-АЛКОКСИПИРИДОПИРИМИДИНЫ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АКТИВНОСТЬЮ ИНГИБИТОРОВ КИНАЗЫ МАР р38
DE60331367D1 (de) 2002-12-30 2010-04-01 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
PT2476667E (pt) * 2003-02-26 2014-09-18 Sugen Inc Compostos de aminoheteroarilo como inibidores da proteína quinase
CN1774250A (zh) * 2003-04-16 2006-05-17 霍夫曼-拉罗奇有限公司 作为治疗诸如类风湿性关节炎的炎性疾病的p38激酶抑制剂的(6－(苯氧基)－吡啶并[3,4－d]嘧啶－2－基)－胺衍生物
EP1685131B1 (fr) * 2003-11-13 2007-03-07 F. Hoffmann-La Roche AG Pyrido-7-pyrimidin-7-ones substitues hydroxyalkyle
EP1831215A1 (fr) * 2004-11-23 2007-09-12 Ranbaxy Laboratories Limited Pyrido[2, 3-d]pyrimidines utilisees comme agents anti-inflammatoires
US20060142312A1 (en) * 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
US20090036472A1 (en) * 2005-02-02 2009-02-05 Palle Venkata P Azabicyclo derivatives as anti-inflammatory agents
WO2006119504A2 (fr) * 2005-05-04 2006-11-09 Renovis, Inc. Composes heterocycliques fusionnes, leurs compositions et leurs utilisations
DE602006010564D1 (de) * 2005-07-21 2009-12-31 Hoffmann La Roche Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
PL2099797T3 (pl) * 2005-08-09 2011-03-31 Irm Llc Związki i kompozycje jako inhibitory kinaz białkowych
US8686002B2 (en) 2005-08-21 2014-04-01 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as binding partners for 5-HT5 receptors
JO2783B1 (en) * 2005-09-30 2014-03-15 نوفارتيس ايه جي Compounds 2-Amino-7, 8-dihydro-6H-Bayredo (3,4-D) Pyrimidine-5-Ones
WO2008150260A1 (fr) * 2007-06-06 2008-12-11 Gpc Biotech, Inc. Inhibiteurs de kinase
WO2008078249A1 (fr) * 2006-12-21 2008-07-03 Ranbaxy Laboratories Limited Agents anti-inflammatoires
AU2008248296B2 (en) 2007-05-07 2011-12-01 Amgen Inc. Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators, process for their preparation, and their pharmaceutical use
CN101679211A (zh) 2007-06-15 2010-03-24 霍夫曼-拉罗奇有限公司 用于制备3-氨基-戊-1,5-二醇的新方法
WO2009117156A1 (fr) 2008-03-21 2009-09-24 Amgen Inc. Composés de pyrazolo-pyrazinones et leurs procédés d’utilisation
EP2112150B1 (fr) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Inhibiteurs Raf améliorés
WO2010046273A2 (fr) * 2008-10-22 2010-04-29 F. Hoffmann-La Roche Ag Inhibiteurs pyrimidinylpyridone de jnk
US8674095B2 (en) 2008-12-19 2014-03-18 Afraxis Holdings, Inc. Compounds for treating neuropsychiatric conditions
WO2011044535A2 (fr) 2009-10-09 2011-04-14 Afraxis, Inc. 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones pour le traitement de troubles de snc
WO2011075616A1 (fr) 2009-12-18 2011-06-23 Temple University - Of The Commonwealth System Of Higher Education Pyrido[2,3-d]pyrimidin-7(8h)-ones substitués et leurs utilisations thérapeuthiques
EP3172214B1 (fr) 2014-07-26 2020-05-13 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido [2,3-d]pyrimidin -7 (8h)-one utilisés en tant qu'inhibiteurs de cdk et utilisations de ceux-ci
UA123914C2 (uk) 2016-06-08 2021-06-23 Суппорт-Венче Гмбх Фармацевтичні комбінації для лікування раку
UA124804C2 (uk) 2016-08-15 2021-11-24 Пфайзер Інк. Піридопіримідинонові інгібітори cdk2/4/6
AU2017313296A1 (en) * 2016-08-17 2019-02-14 Support-Venture Gmbh Method of preventing or treating hearing loss
WO2018132550A1 (fr) 2017-01-11 2018-07-19 The General Hospital Corporation Agents d'imagerie à canaux sodiques dépendant de la tension
AU2018248578A1 (en) 2017-04-04 2019-10-17 Kinarus Ag Methods of preventing or treating ophthalmic diseases
JP2021501123A (ja) * 2017-08-31 2021-01-14 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｅｇｆｒおよび／またはｈｅｒ２の阻害剤ならびに使用方法
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
NZ762856A (en) 2017-10-05 2020-07-31 Fulcrum Therapeutics Inc P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
US20210261547A1 (en) * 2018-06-27 2021-08-26 Tufts Medical Center, Inc. Pyridopyrimidine compounds and methods of their use
AU2019300135A1 (en) 2018-07-13 2021-01-28 Kinarus Ag Combinations of PPAR agonists and p38 kinase inhibitors for preventing or treating fibrotic diseases
TW202112368A (zh) 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 用於治療有關dux4表現之疾病的抑制劑組合
US20230263803A1 (en) 2020-08-11 2023-08-24 Kinarus Ag Methods of preventing or treating covid-19 and related viral diseases or disorders

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215216A (en) 1979-04-18 1980-07-29 American Home Products Corporation 7,8-Dihydro-2,5,8-trisubstituted-7-oxo-pyrido[2,3-d]pyrimidine-6-carboxylic acid derivatives
US5037826A (en) 1986-10-15 1991-08-06 Schering Corporation 1-substituted naphthyridine and pyridopyrazine derivatives
GB8702758D0 (en) * 1987-02-06 1987-03-11 Wellcome Found Treatment of disease
AU598093B2 (en) 1987-02-07 1990-06-14 Wellcome Foundation Limited, The Pyridopyrimidines, methods for their preparation and pharmaceutical formulations thereof
WO1993017682A1 (fr) 1992-03-04 1993-09-16 Abbott Laboratories Antagonistes des recepteurs de l'angiotensine ii
IL115256A0 (en) 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
ES2146782T3 (es) 1994-11-14 2000-08-16 Warner Lambert Co 6-aril-pirido(2,3-d)pirimidinas y naftiridinas para la inhibicion de la proliferacion celular inducida por la proteina tirosina quinasa.
US5620981A (en) 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
US6147080A (en) * 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
EP0964864B1 (fr) 1997-02-05 2008-04-09 Warner-Lambert Company LLC Pyrido 2,3d pyrimidines et 4-aminopyrimidines en tant qu'inhibiteurs de la proliferation cellulaire
US5945422A (en) 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
TW458977B (en) * 1997-04-16 2001-10-11 Abbott Lab 6,7-disubstituted-4-aminopyrido[2,3-D] pyrimidine compounds
AU7108398A (en) 1997-04-16 1998-11-11 Abbott Laboratories 5,7-disubstituted 4-aminopyrido{2,3-d}pyrimidine compounds and their use as adenosine kinase inhibitors
CN1252069A (zh) 1997-04-16 2000-05-03 艾博特公司 5,6,7－三取代的－4－氨基吡啶并[2,3－d]嘧啶化合物
PL344248A1 (en) 1998-05-26 2001-10-22 Warner Lambert Co Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
AU3951899A (en) 1998-06-19 2000-01-05 Pfizer Products Inc. Pyrrolo(2,3-d)pyrimidine compounds
ES2258431T3 (es) 1999-08-02 2006-09-01 F. Hoffmann-La Roche Ag Proceso para la preparacion de derivados de benzotiofeno.
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
MXPA02008535A (es) * 2000-03-06 2002-12-13 Warner Lambert Co Inhibidores de 5-alquilpirido (2.3-d) pirimidinas tirosina quinasa.
US6518276B2 (en) * 2000-08-31 2003-02-11 Syntex (U.S.A.) Llc 7-oxo-pyridopyrimidines (II)
CA2434834C (fr) 2001-02-12 2010-09-14 F. Hoffmann-La Roche Ag Pyrido-pyrimidines substituees en position 6
DK1470124T3 (da) * 2002-01-22 2006-04-18 Warner Lambert Co 2-(Pyridin-2-yl amino)-pyrido[2,3]pyrimidin-7-oner

Also Published As

Publication number Publication date
KR20040018254A (ko) 2004-03-02
CN1503672A (zh) 2004-06-09
MXPA03007166A (es) 2003-11-18
CA2434834C (fr) 2010-09-14
ATE305303T1 (de) 2005-10-15
US6696566B2 (en) 2004-02-24
BRPI0207172B1 (pt) 2019-04-09
EP1361880A2 (fr) 2003-11-19
AR035854A1 (es) 2004-07-21
JP4064818B2 (ja) 2008-03-19
YU63703A (sh) 2006-05-25
WO2002064594A3 (fr) 2003-01-09
CN100376571C (zh) 2008-03-26
DK1361880T3 (da) 2006-01-23
US7169794B2 (en) 2007-01-30
WO2002064594A2 (fr) 2002-08-22
HRP20030624B1 (en) 2007-03-31
US20070135458A1 (en) 2007-06-14
RU2003125887A (ru) 2005-03-20
RU2269527C2 (ru) 2006-02-10
MY131518A (en) 2007-08-30
NO20033540L (no) 2003-08-11
AU2002256615B2 (en) 2007-09-13
ES2249574T3 (es) 2006-04-01
IL156872A (en) 2009-07-20
HUP0303458A2 (hu) 2004-01-28
IL156872A0 (en) 2004-02-08
CZ20032416A3 (cs) 2004-07-14
NO326133B1 (no) 2008-10-06
NO20033540D0 (no) 2003-08-11
US20040116698A1 (en) 2004-06-17
SK11322003A3 (en) 2004-10-05
PA8539201A1 (es) 2004-08-31
PL366918A1 (en) 2005-02-07
BRPI0207172B8 (pt) 2021-05-25
MA26993A1 (fr) 2004-12-20
PE20020976A1 (es) 2002-10-29
JP2004525896A (ja) 2004-08-26
KR100639772B1 (ko) 2006-10-30
JO2410B1 (en) 2007-06-17
HU229604B1 (en) 2014-02-28
ZA200305938B (en) 2005-01-26
US20030171584A1 (en) 2003-09-11
HRP20030624A2 (en) 2005-06-30
EP1361880B1 (fr) 2005-09-28
BR0207172A (pt) 2004-03-30
DE60206363T2 (de) 2006-07-06
NZ526961A (en) 2005-03-24
US7449581B2 (en) 2008-11-11
HUP0303458A3 (en) 2012-12-28
CA2434834A1 (fr) 2002-08-22
DE60206363D1 (de) 2006-02-09

Similar Documents

Publication Publication Date Title
DE60217162D1 (en) Tetrafluorethen-perfluorbutylethen-copolymer
DE60209787D1 (en) Flächiges implantat
DE50202400D1 (en) Baw-resonator
DE50201180D1 (en) Organopolysiloxan/polyharnstoff/polyurethan-blockcopolymere
DE60213216D1 (en) Metalloproteinaseinhibitoren
DE50209614D1 (en) 2-heteroarylcarbonsäureamide
DE60217478D1 (en) Sychrongleichrichter
DE50211022D1 (en) Heteroarylcarbonsäureamide
HK1066170A1 (en) 6-substitued pyrido-pyrimidines
DE60214551D1 (en) Modulares airbagaufblassystem
DE60210819D1 (en) Pyrazolopyridazinderivate
DE60141364D1 (en) Polyphenylensulfidharzzusammensetzung
DE60141362D1 (en) Ösophagus-stoma-knopf
DE50202633D1 (en) Ophthalmoskop
AU2002360430A8 (en) 14-methyl-epothilones
DE60107296D1 (en) Kabelverstärkerverbindungsanordnung
DE60204140D1 (en) 5-ethyl-imidazotriazinone
DE60216319D1 (en) Heteroaryl-substituierte aminocyclohexan-derivate
DE50206483D1 (en) Displaymodul
DE50203686D1 (en) Substituierte c-furan-2-yl-methylamin- und c-thiophen-2-yl-methylamin-derivate
DE50201028D1 (en) Diarylgelbpigmentpraeparationen
DE50214962D1 (en) Heterocyclylarylsulfonamide
DE60206072D1 (en) Aroylpyridinone
AU2002313943A8 (en) Electromobile
AU2001100134A4 (en) Enviro-trap

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20120204